This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

RiXtrema Expands Tail Risk Research Capabilities

NEW YORK, March 27, 2013 /PRNewswire/ -- RiXtrema, Inc. ( www.rixtrema.com), a leading  risk management modeling and software provider to the investment management industry, is pleased to announce today the addition of Dr. Yaacov Kopeliovich and Dr. Barry Schachter to the research team.

Dr. Kopeliovich, who joins RiXtrema as a Director of Research, has extensive experience with the real world behavior of complex financial instruments during crisis events. "Yaacov's mathematical background, his derivative experience at MEAG and his focus on overcoming the deficiencies of traditional investment models make him an invaluable asset to RiXtrema as we continue to build state-of-the-art tail risk systems for the 21 st century," stated Daniel Satchkov, RiXtrema's President and Founder.

Dr. Kopeliovich added, "I am delighted to have joined such an impressive firm and a superb cast of innovative, dedicated, and ethical individuals. I very much look forward to helping the asset management industry in attaining a deeper understanding and better management of tail risks."

Dr. Schachter, who is assuming a Senior Advisor role on RiXtrema's Scientific Advisory Board, is a legendary risk manager who brings with him a wealth of experience, having spent his career leading risk groups at a number of prominent hedge funds, including most recently as a Chief Risk Officer at Woodbine Capital Advisors. Dr. Schachter said, "RiXtrema is truly unique in its approach to risk analysis, and I am excited to have the opportunity to bring new and exciting research into everyday risk management practice."

Mr. Satchkov shared his thoughts on the addition of Dr. Schachter to the RiXtrema team, "Barry shares our desire for innovation in risk analysis. His research and practical expertise will be applied to developing new uses for groundbreaking products like RiXtrema's Reverse Stress Testing. He will join experts like Dr. Jon Danielsson of LSE in working closely with Dr. Kopeliovich and the rest of the research team to provide a fresh look at tail risks facing the asset managers."

Dr. Schachter received his M.A. and Ph.D. from Cornell University, and received his BS from Bentley University. Additionally, he currently serves on the Editorial Board of the Journal of Derivatives and maintains one of the longest running risk websites at Gloria-Mundi.com. He is also a Fellow of the Program in Mathematics in Finance at NYU's Courant Institute and a Research Associate at the EDHEC Business School.

Dr. Kopeliovich received his Masters in Financial Engineering from the Hass School of Business at the University of California, Berkley, his B.S., M.S. and Ph. D. in Mathematics from Hebrew University, Jerusalem, Israel and is currently studying for his Ph. D. in Finance from EDHEC Business School, Nice, France.

About RiXtrema, Inc. based in New York, is a risk management modeling and software provider to the investment management industry. RiXtrema works with pension plans and consultants, mutual funds, hedge funds, funds of funds and other asset managers to implement and support a carefully structured risk management process focusing on diversification in periods of extreme volatility.

SOURCE RiXtrema, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,991.26 +278.60 1.57%
S&P 500 2,086.34 +25.32 1.23%
NASDAQ 4,944.4990 +53.28 1.09%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs